Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Hiromitsu Imai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ethics, Oita University Faculty of Medicine, Oita, Japan. Hauptthemen laut MEDLINE: Rifampin, Cross-Over Studies, Drug Interactions, Area Under Curve. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EA Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kissei.
Abstract (Originalsprache)
Aims
To evaluate the effect of the combination of carotegrast methyl with rifampicin, a potent inhibitor of organic anion transporter polypeptide, on the pharmacokinetics (PKs), safety and tolerability of carotegrast methyl.
Methods
In this 2 × 2 crossover study in 20 healthy Japanese adults, 10 subjects received carotegrast methyl 960 mg and rifampicin 600 mg on day 1 and received carotegrast methyl 960 mg on day 8. The subjects in the other sequence received the same treatments but in the opposite order. The 90% confidence interval (CI) of the geometric mean ratio of the C max and AUC 0‐ t for carotegrast, the main active metabolite of carotegrast methyl, with/without rifampicin was calculated. If the 90% CI fell within the range of 0.80‐1.25, this indicated the absence of any drug‐drug interaction. Adverse events (AEs) were monitored.
Results
The geometric mean ratios (90% CI) of the C max and AUC 0‐ t for carotegrast with/without rifampicin were 4.78 (3.64‐6.29) and 5.59 (4.60‐6.79), respectively, indicating that carotegrast has a PK interaction with rifampicin. The combination with rifampicin increased the exposure of carotegrast and also that of its metabolites. The incidence of any AEs with/without rifampicin was five (25.0%) and one (5.0%), respectively.
Conclusions
Coadministration of carotegrast methyl with rifampicin significantly increased the exposure of carotegrast compared with carotegrast methyl administration alone. In this single dose study, the incidence of AEs of carotegrast methyl with rifampicin increased compared with carotegrast methyl alone, but the incidence of adverse drug reactions did not increase with combination administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Ethics, Oita University Faculty of Medicine, Oita, Japan.
- Clinical Development Department, EA Pharma Co., Ltd., Tokyo, Japan.
- Department of Clinical Research Center, Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan.
Förderung
- EA Pharma Co., Ltd.
- Kissei Pharmaceutical Co., Ltd.
- Kissei
Zitieren
APA
Imai, H., Oikawa, I., Koyama, T., & Matsuki, S. (2024). Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16024
Vancouver
Imai H, Oikawa I, Koyama T, Matsuki S. Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16024
BibTeX
@article{Imai2024,
author = {Imai, Hiromitsu and Oikawa, Ichiro and Koyama, Tetsuya and Matsuki, Shunji},
title = {Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16024}
}
EUVIMED